|
EP2952520A1
|
|
Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides.
|
|
EP2936122A1
|
|
Methods and means for detecting cells using surface plasmon resonance
|
|
EP2520662A1
|
|
Means and methods to determine a risk of multiple organ failure
|
|
WO2011074965A1
|
|
Methods and means for counteracting an activity of an fc domain
|
|
EP2362882A1
|
|
Detecting antigen responsive cells in a sample
|
|
WO2010025756A1
|
|
Reaction vessel capable of detecting carrier-bound analyte complexes, method for detecting carrier-bound analyte complexes, and kit of parts
|
|
EP2111869A1
|
|
Compositions and methods to enhance the immune system
|
|
WO2009089846A1
|
|
Methods for increasing the therapeutic efficacy of immunoglobulin g class 3 (igg3) antibodies
|
|
CA2712021A1
|
|
Methods and kits for detecting antibodies against therapeutic antibodies
|
|
EP1806395A1
|
|
Maturation of dendritic cells
|
|
EP1801234A1
|
|
Diagnostic methods involving determining gene copy numbers and use thereof
|
|
EP1591534A1
|
|
A method of genotyping blood cell antigens and a kit suitable for genotyping blood cell antigens
|
|
EP1571449A1
|
|
Prion immunoassay and separation method
|
|
AU2003237076A1
|
|
Therapeutical use of anti-cd70 antibody for treating or preventing aids
|
|
EP1462804A1
|
|
Method for the detection of a pathogenic form of a prion protein
|
|
WO03042239A1
|
|
Peptides inhibiting signaling by ras-like gtpases
|
|
EP1382690A1
|
|
Method to reduce false positive outcomes in prion assays
|
|
EP1170589A1
|
|
Method for histocompatibility testing
|
|
EP1095143A2
|
|
Inhibitor for diagnosis and treatment of haemophilia a patients
|
|
AU3059499A
|
|
Solid-phase method for antigen and antibody determinations in bloodgroup serology, and test kit
|
